Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We were able to deliver results consistent with or better than our commitments to stakeholders, and look forward to managing our business for more of the same in 2024 |
| We also made good progress on margins in 2023, improving our EBITDA margins by 70 basis points, more than offsetting growth investments and headwinds from M&A currency inflation |
| 2023 was a year of significant progress toward our long-term strategic goals, and I'm excited about the future of our high-value med tech growth company |
| We had a terrific year with continued share gains across geographies and business units, strong execution on new product initiatives, solid margin expansion, and truly transformative acquisitions |
| I think the reason people are really excited about AR is because it's -- ultimately, surgeons are looking for things that are going to improve the way that they can take a surgical plan and flow it interoperatively in surgery, make the decision they want to make, capture all that data while they're doing that, and have that ability to do efficient repeatable surgery and capture all the data |
| The improvements that we made last year after the initial launch are -- really have improved the usability |
| In Recon, we made considerable progress expanding this high-growth and high-margin platform and drove full year organic growth of 14% |
| We delivered double-digit organic growth across all major segments, continued to win in the ASC in the U.S., and had strong execution internationally as we continue to ramp our very successful 2021 Mathys acquisition |
| In P&R, we've been reshaping the business for sustained mid-single-digit organic growth |
| But if I look at my -- the way at least we model, even consensus, EBITDA is much better, which is great |
| We improved innovation vitality in this business from close to 0 in 2018 to double digits as we exit 2023, and have a strong pipeline for 2024 and beyond |
| And you can see that extra in our very strong 14% growth for the year |
| Our gross margin improvement is a result of our mix-enriching strategy and the powerful impact of our EGX business system driving operational productivity and pricing improvements |
| But again, in terms of the kind of the macro level picture, again, we see really strong EBITDA margin improvement lift by adding Lima plus getting the core expansions that we've also talked about |
| We've got nice growth of Hip, but the Knee growth is still is very strong |
| We expanded geographically and enhanced our innovation capabilities with Lima and NovaStep, and we continue to follow our proven EGX playbook to make sure each acquisition delivers strong strategic impact, financial contributions and long-term shareholder returns |
| And so it's a very kind of healthy period in terms of our ability to drive vitality across all of the businesses |
| Kind of a similar picture as we get over into the knee space, our EMPOWR 3D with its dual pivot capability has shown to be a better need that leads to better patient satisfaction |
| We continued our trend of double-digit growth and share gain in Recon as our markets had normal seasonality |
| We believe the elective surgery markets we serve remain healthy, with higher-than-normal procedural demand in early 2023 and the potential for above normal demand again in 2024 |
| In P&R, we had another strong quarter, showing our reestablished leadership in these markets with global share gain and a stable market environment, plus a bit of tailwind from the light prior year comp |
| We expanded our gross margins by 150 basis points, reflecting continued impacts from productivity, mix and the scaling of recent acquisitions |
| Overall, we exited 2023 with strong momentum in line with our strategic goals and are excited for a great 2024 |
| And we're very excited about the 3D printing |
| Outside the U.S., we grew 11% organically in a resilient market |
| We have a very strong Recon innovation pipeline that will allow us to continue to gain share |
| So feeling very good about the start on Lima and the growth in margin picture that's going to emerge from that as we execute through it |
| To summarize, on Slide 14, we had another strong year in 2023 and have been building solid momentum as we turn the page to 2024 |
| We've had terrific feedback from surgeons on all of these great new products |
| In P&R on Slide 6, our organic growth reflects a healthy market environment and disciplined execution, albeit against the easiest comp of the year |
| Statement |
|---|
| Fourth quarter adjusted EBITDA margin of 18% was down 30 basis points versus 2022 |
| And certainly, the shape of the year is going to mirror last year because there's some very, very tough comps early in the year |
| We note that this represents a $0.03 headwind to adjusted earnings per share |
| And I think your prior year comp from last year actually eased a little bit |
| Just starting with 2024 revenue guidance, the 7% core business growth really kind of implies a slight slowdown year-over-year |
| The single upgrade category is a sizable growing segment where we have limited share |
| EPS is a little bit lower, I guess, from a guidance standpoint |
| I think the math suggests that there's still quite a bit of pent-up demand that really wasn't satisfied through the COVID period |
| But I think in the past, you had mentioned the guide assumes some disruption from integration |
| But yes, I mean, the market environment from the front half of last year to the back half of last year was certainly a slower -- an elevated market environment in the first half and then more normal in the back half |
| And so that had some impact and a little bit of deceleration in Knee from Q3 to Q4 |
| We know that it will be a little bit |
| Impacts from recent acquisitions and foreign currency offset our core margin improvement of 130 basis points |
| and bringing some of those technologies Lima has for some of the toughest revisions in shoulder into the U.S |
| We just think it's more prudent not to plan for that |
| And then on Lima, I know your guidance for Lima sales includes some exits of product lines, et cetera |
| The year-over-year decline was driven by onetime cost benefits in 2022 and some dilution from recent acquisitions |
| You got about 1 point tax headwind, so that's about $0.03 |
| And then we also, on the P&R side, had some extra price that we know it's going to start to moderate |
| And so when you look at our growth that was pushing 5% on the full year basis, that's a little bit elevated from what we envisioned being able to do on a go-forward basis in that business |
Please consider a small donation if you think this website provides you with relevant information